Core Points - Eagle Pharmaceuticals, Inc. will hold its 2025 Annual Meeting of Stockholders on October 17, 2025 [1] - The record date for stockholders to participate in the meeting is set for August 18, 2025, at 5 p.m. Eastern Time [1] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial sectors [3] - The company is dedicated to developing innovative medicines that significantly improve patients' lives [3] - Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® through its subsidiary Acacia Pharma Inc. [3] - The oncology and critical care pipeline includes product candidates aimed at addressing underserved therapeutic areas across multiple disease states [3] - The company focuses on developing medicines that could be integrated into the personalized medicine paradigm in cancer care [3]

Core Viewpoint - Eagle Pharmaceuticals has entered into a royalty purchase agreement with Blue Owl Capital to sell its royalty interest in BENDEKA for a total of $69 million before transaction costs, providing immediate capital to the company [1][3][4]. Group 1: Transaction Details - The agreement involves Eagle receiving an upfront payment of $69 million in exchange for a specified amount of its royalty interest in BENDEKA's net sales for the quarter ending December 31, 2024, and 100% of the royalty interest thereafter, capped at 1.3 times the purchase price [4]. - The proceeds from the transaction will be used to fully repay an existing credit agreement, including a $27.5 million term loan and $25 million under a revolving credit facility, with remaining funds allocated for general corporate purposes [5]. Group 2: Product Information - BENDEKA is a ready-to-dilute liquid formulation of bendamustine, approved for treating chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) [2]. - The product is characterized by its low-volume (50 mL) and short infusion time (ten minutes) [2]. Group 3: Company Strategy and Future Plans - The company continues to invest in its R&D programs, including CAL02 for severe community-acquired bacterial pneumonia and EA 114 for hormone-receptor-positive metastatic breast cancer [6]. - The transaction is seen as a strategic move to enhance the company's financial position and support ongoing research initiatives [3]. Group 4: Advisory and Legal Support - Armentum Partners, LLC acted as the financial advisor for Eagle on this transaction, while Latham & Watkins LLP provided legal counsel to Eagle, and Gibson, Dunn & Crutcher LLP represented Blue Owl [7]. Group 5: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines with a portfolio that includes products like PEMFEXY®, RYANODEX®, and BENDEKA® [8]. - The company aims to address underserved therapeutic areas across multiple disease states and is committed to personalized medicine in cancer care [8].

Core Viewpoint - Eagle Pharmaceuticals, Inc. has amended its limited duration stockholder rights plan to increase the initial purchase price of each preferred share purchase right from $10.00 to $20.00, effective immediately, in response to significant dislocation in the trading price of its common stock [1][2]. Group 1: Rights Plan Details - The Rights Plan is designed to penalize any person or group acquiring 10% or more of the company's common stock without Board approval, with a higher threshold of 15% for passive institutional investors [2]. - The amendment increases the potential dilution an Acquiring Person would face if the Rights Plan is triggered, thereby protecting stockholders' long-term investment value [2]. - The Rights Plan will automatically expire on October 30, 2025, unless earlier redeemed or exchanged by the company [3]. Group 2: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial operations [4]. - The company is focused on developing innovative medicines, particularly in oncology and critical care, with products like PEMFEXY®, RYANODEX®, and others in its pipeline [4].